ArticleViruses2021
Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06368388 (Bacteriophage Therapy for Difficult-to-treat Infections), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a Multidisciplinary Phage Task Force
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- First UK use of bacteriophage therapy with DAIR for chronicASM case reports · 2026Article
- Bacteriophage Therapy for Breast Implants: A Translational Perspective and Future Directions.Plastic and reconstructive surgery. Global open · 2026Article
- Phage therapy in revision arthroplasty: State of the art and application protocols.Arthroplasty (London, England) · 2026Review
- Prolonged disease remission of the chronic immunological skin disorder hidradenitis suppurativa with adjunctive bacteriophage therapy.Nature communications · 2025Article
- PEGylation Overcomes Pharmacological Barriers to Improve Systemic Pharmacokinetics and Therapeutic Efficacy of Phages against MDRJournal of microbiology and biotechnology · 2025Article
- Phage Therapy forAntibiotics (Basel, Switzerland) · 2025Review
- Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities.Bioengineering (Basel, Switzerland) · 2025Review
- Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.The Journal of clinical investigation · 2025Review
- Evaluating the safety, pharmacokinetics and efficacy of phage therapy in treating fracture-related infections with multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Challenges and opportunities of phage therapy forApplied and environmental microbiology · 2024Review
- Transmission Dynamics and Novel Treatments of High Risk Carbapenem-ResistantPharmaceuticals (Basel, Switzerland) · 2024Review
- Bacterial persisters: molecular mechanisms and therapeutic development.Signal transduction and targeted therapy · 2024Review
- Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.Nature microbiology · 2024Observational
- Exploring the Impact of Airway Microbiome on Asthma Morbidity: A Focus on the "Constructing a 'Eubiosis Reinstatement Therapy' for Asthma-CURE" Project.Pulmonary therapy · 2024Review
- Bacteriophage therapy in musculoskeletal infections: from basic science to clinical application.EFORT open reviews · 2024Review
- Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University.Scientific reports · 2024Article
- Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective.Frontiers in cellular and infection microbiology · 2024Observational
- Exploring the potential of naturally occurring antimicrobials for managing orthopedic-device-related infections.Journal of bone and joint infection · 2024Review
- Isolation and Characterization of theMicroorganisms · 2023Article
- Bacteriophages in Infectious Diseases and Beyond-A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In times where only a few novel antibiotics are to be expected, antimicrobial resistance remains an expanding global health threat. In case of chronic infections caused by therapy-resistant pathogens, physicians have limited therapeutic options, which are often associated with detrimental consequences for the patient. This has resulted in a renewed interest in alternative strategies, such as bacteriophage (phage) therapy. However, there are still important hurdles that currently impede the more widespread implementation of phage therapy in clinical practice. First, the limited number of good-quality case series and clinical trials have failed to show the optimal application protocol in terms of route of administration, frequency of administration, treatment duration and phage titer. Second, there is limited information on the systemic effects of phage therapy. Finally, in the past, phage therapy has been applied intuitively in terms of the selection of phages and their combination as parts of phage cocktails. This has led to an enormous heterogeneity in previously published studies, resulting in a lack of reliable safety and efficacy data for phage therapy. We hereby present a study protocol that addresses these scientific hurdles using a multidisciplinary approach, bringing together the experience of clinical, pharmaceutical and molecular microbiology experts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.